GlobalData on MSN23h
Aclaris Therapeutics secures global rights to Biosion’s antibodiesAclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...
Hosted on MSN22h
Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment JumpsAclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered ...
Leerink Partners has recently raised Aclaris Therapeutics Inc (ACRS) stock to Outperform rating, as announced on Today, according to Finviz. Earlier, on Today, Jefferies had raised the stock from a ...
WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage ...
Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...
BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...
Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clinical proof of concept in atopic dermatitis, which is ...
Leerink upgraded Aclaris Therapeutics (ACRS) to Outperform from Market Perform with a price target of $7, up from $2, representing over 120% ...
Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...
Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...
1d
BTIG analyst Julian Harrison upgraded the rating on Aclaris Therapeutics (ACRS – Research Report) to a Buy yesterday, setting a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback